ArticleThe pharmacogenomics journal2013
Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3.
Article in The pharmacogenomics journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 94 citations in OpenAlex.
- Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial.Medical oncology (Northwood, London, England) · 2021Trial
- Protein expression of ABCC2 and SLC22A3 associates with prognosis of pancreatic adenocarcinoma.Scientific reports · 2019Trial
- Pharmacogenetic Analysis of the Model-Based Pharmacokinetics of Five Anti-HIV Drugs: How Does This Influence the Effect of Aging?Clinical and translational science · 2018Trial
- Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer.Nature communications · 2026Article
- Interindividual variability in metformin pharmacokinetics in pediatric patients.Pediatric research · 2026Article
- SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer.Cell reports · 2026Article
- The population-specific Thr44Met OCT3 coding variant affects metformin pharmacokinetics with subsequent effects on insulin sensitivity in C57Bl/6J mice.Diabetologia · 2025Article
- Identification of Mitophagy-Related Genes and Analysis of Immune Infiltration in Atherosclerosis.Journal of inflammation research · 2025Article
- Impact of genetic variants in the solute carrier (Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Genetic preservation of SLC22A3 in the Admixed and Xhosa populations living in the Western Cape.Molecular biology reports · 2023Article
- Combining Molecular Subtypes with Multivariable Clinical Models Has the Potential to Improve Prediction of Treatment Outcomes in Prostate Cancer at Diagnosis.Current oncology (Toronto, Ont.) · 2022Article
- SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia.Clinical epigenetics · 2022Article
- Structural basis of organic cation transporter-3 inhibition.Nature communications · 2022Article
- Article
- Article
- Functional inhibition of Oct leads to HNF4α upregulation.Experimental and therapeutic medicine · 2021Article
- LncRNA PAINT is associated with aggressive prostate cancer and dysregulation of cancer hallmark genes.International journal of cancer · 2021Article
- Contribution and Expression of Organic Cation Transporters and Aquaporin Water Channels in Renal Cancer.Reviews of physiology, biochemistry and pharmacology · 2021Review
- DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.Clinical and translational science · 2021Article
- The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
Human organic cation transporter 3 (OCT3 and SLC22A3) mediates the uptake of many important endogenous amines and basic drugs in a variety of tissues. OCT3 is identified as one of the important risk loci for prostate cancer, and is markedly underexpressed in aggressive prostate cancers. The goal of this study was to identify genetic and epigenetic factors in the promoter region that influence the expression level of OCT3. Haplotypes that contained the common variants, g.-81G>delGA (rs60515630) (minor allele frequency 11.5% in African American) and g.-2G>A (rs555754) (minor allele frequency>30% in all ethnic groups) showed significant increases in luciferase reporter activities and exhibited stronger transcription factor-binding affinity than the haplotypes that contained the major alleles. Consistent with the reporter assays, OCT3 messenger RNA expression levels were significantly higher in Asian (P<0.001) and Caucasian (P<0.05) liver samples from individuals who were homozygous for g.-2A/A in comparison with those homozygous for the g.-2G/G allele. Studies revealed that the methylation level in the basal promoter region of OCT3 was associated with OCT3 expression level and tumorigenesis capability in various prostate cancer cell lines. The methylation level of the OCT3 promoter was higher in 62% of prostate tumor samples compared with matched normal samples. Our studies demonstrate that genetic polymorphisms in the proximal promoter region of OCT3 alter the transcription rate of the gene and may be associated with altered expression levels of OCT3 in human liver. Aberrant methylation contributes to the reduced expression of OCT3 in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.